RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

Review article

The Messenger RNA (mRNA) Revolution: From Fundamental Biology to Therapeutic Applications and Future Horizons

***Abouelhag H. A.* ***

*Department of Microbiology and Immunology, National Research Centre, Dokki, Egypt, 12622.

Received: 17-11-2025 **Accepted:** 20-01-2025 **Published online:** 30-01-2026
DOI: https://doi.org/10.33687/ricosbiol.04.01.106

Abstract

Messenger RNA (mRNA) has evolved from a fundamental biological intermediary to a versatile platform for therapeutic and prophylactic interventions. This review provides a comprehensive analysis of the mRNA field, beginning with the essential biology of natural mRNA processing and regulation. We detail the key engineering breakthroughs that transformed synthetic mRNA into a viable drug modality, including nucleoside modifications and sequence optimization to enhance stability and translational efficiency while modulating immunogenicity (Karikó, Buckstein, Ni, & Weissman, 2005; Pardi, Hogan, Porter, & Weissman, 2018). A critical discussion of delivery technologies, with a focus on lipid nanoparticles (LNPs), explains how these carriers enable *in vivo* application (Hou, Zaks, Langer, & Dong, 2021). The review then surveys the expansive therapeutic landscape, from the paradigm-shifting success of COVID-19 vaccines (Polack et al., 2020) to applications in protein replacement therapy, cancer immunotherapy, and gene editing. Finally, we examine persistent challenges—including delivery refinement, durability of response, and scaling manufacturing and envision future directions such as circular RNA, personalized neoantigen vaccines, and programmable protein therapeutics. The convergence of mRNA biology, chemistry, and delivery science heralds a new era in medicine with the potential to address a vast array of human diseases.

Keywords: mRNA, synthetic mRNA, mRNA therapeutics, lipid nanoparticles (LNPs), vaccinology, *in vitro* transcribed (IVT) mRNA, epitranscriptomics, RNA delivery, personalized medicine.

Introduction

1. The Central Dogma and the Historical Discovery of mRNA

The "Central Dogma" of molecular biology, articulated by Francis Crick, posits the unidirectional flow of genetic information from DNA to RNA to protein. The discovery of messenger RNA (mRNA) as the crucial intermediary in this pathway was a landmark achievement. In 1961, Sydney Brenner, François Jacob, and Matthew Meselson, through experiments on bacteriophage-infected E. coli, identified an unstable RNA fraction that carried genetic information from DNA to the ribosomes for protein synthesis (Brenner, Jacob, & Meselson, 1961). This ephemeral molecule, later termed messenger RNA, was characterized by its base sequence complementary to DNA and its rapid turnover, allowing cells to dynamically adjust their proteome in response to stimuli.

2. The Conceptual Leap: mRNA as a Therapeutic Platform

For decades, mRNA was studied primarily as a target for understanding gene regulation. The visionary idea of using synthetic mRNA as a drug emerged in the 1990s. Pioneering work by scientists like Jon Wolff demonstrated that *in vitro* transcribed (IVT) mRNA could be delivered to cells and animals to produce a functional protein (Wolff et al., 1990). However, major hurdles—namely, intrinsic immunogenicity triggering inflammatory responses, rapid enzymatic degradation, and inefficient *in vivo* delivery—stymied progress. The transformative breakthrough came with the discovery that incorporating modified nucleosides (e.g., pseudouridine) into IVT mRNA dramatically reduced its recognition by pattern recognition receptors, suppressing unwanted interferon responses and enhancing protein production (Karikó et al., 2005). This, coupled with advances in nanocarrier delivery, propelled mRNA from a laboratory tool to a clinical reality.

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

3. The COVID-19 Catalyst and Beyond

The SARS-CoV-2 pandemic served as an unprecedented validation and accelerator for mRNA technology. The rapid development, stunning efficacy, and global deployment of mRNA-based COVID-19 vaccines (mRNA-1273 and BNT162b2) demonstrated the platform's key advantages: speed (design based on sequence alone), flexibility (easy targeting of new variants), potency (strong humoral and cellular immunity), and scalable manufacturing (Polack et al., 2020; Corbett et al., 2020). This success has unleashed vast investment and interest, expanding the therapeutic horizon far beyond infectious diseases.

4. Scope and Aims of This Review

This article aims to provide a holistic overview of the mRNA revolution. We will first elucidate the biology of natural mRNA to establish a foundational understanding. We will then dissect the engineering principles behind synthetic mRNA and the delivery technologies that make it functional *in vivo*. A comprehensive survey of current and emerging therapeutic applications will follow. Finally, we will confront the remaining challenges and outline future research directions that will define the next decade of mRNA-based medicine.

The Biology of Natural mRNA: Structure, Processing, and Function

1. Canonical Structure and Function of mRNA Elements

A mature eukaryotic mRNA is a complex ribonucleoprotein particle with distinct functional regions:

i. 5' Cap (7-methylguanosine): Protects from 5' exonucleases, facilitates ribosome binding during translation initiation, and is involved in splicing and nuclear export.

ii. 5' Untranslated Region (UTR): Contains regulatory elements that control translation efficiency, stability, and subcellular localization. Secondary structures in the 5' UTR can influence ribosome scanning (Leppek et al., 2022).

iii. Coding Sequence (CDS): The open reading frame that specifies the amino acid sequence of the protein. Codon usage within the CDS can affect translation speed and fidelity (Gustafsson, Govindarajan, & Minshull, 2004).

iv. 3' Untranslated Region (UTR): A critical hub for post-transcriptional regulation, containing binding sites for microRNAs (miRNAs) and RNA-binding proteins (RBPs) that govern mRNA stability, localization, and translation. AU-rich elements (AREs) in 3' UTRs are classic destabilizing motifs.

v. Poly(A) Tail: A stretch of adenosines at the 3' end, added by poly(A) polymerase. It protects against 3' exonuclease degradation and synergizes with the 5' cap to enhance translation by promoting circularization of the mRNA via the cap-binding complex (eIF4F) and poly(A)-binding protein (PABP).

2. mRNA Biogenesis: From Transcription to Maturation

mRNA production is a tightly coordinated, multi-step process:

i. Transcription: RNA Polymerase II synthesizes a precursor mRNA (pre-mRNA).
ii. 5' Capping: The 5' cap is added co-transcriptionally.
iii. Splicing: The spliceosome removes non-coding introns and ligates exons. Alternative splicing generates multiple protein isoforms from a single gene.
iv. 3' End Processing and Polyadenylation: The pre-mRNA is cleaved, and the poly(A) tail is added.
v. Nuclear Export: The mature mRNA, bound by export factors, is transported through nuclear pore complexes to the cytoplasm.
vi. Quality Control: Surveillance mechanisms like nonsense-mediated decay (NMD) detect and destroy mRNAs with premature stop codons, preventing the production of truncated proteins.

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

3. Regulation of mRNA Fate and Translation

mRNA levels and translation are dynamically controlled. Cytoplasmic mRNA half-lives range from minutes to hours. Key regulators include:

i. miRNAs: Short non-coding RNAs that bind to complementary sequences in the 3' UTR, typically leading to translational repression and mRNA deadenylation/decay.
ii. RNA-Binding Proteins (RBPs): Hundreds of RBPs bind to specific motifs in UTRs, forming ribonucleoprotein complexes that dictate the mRNA's fate—its stability, localization to specific subcellular compartments (e.g., axons, dendrites), and translation rate in response to cellular signals.

Engineering Synthetic mRNA: From IVT to a Refined Drug Substance

1. *In Vitro* Transcription (IVT): The Production Engine

Synthetic mRNA is produced enzymatically in a cell-free system, a process standardized from molecular biology techniques (Beckert & Masquida, 2011). The reaction requires a linearized DNA template containing a bacteriophage promoter (T7, SP6, or T3) followed by the desired sequence: optimized 5' UTR, codon-optimized CDS, 3' UTR, and a poly(dT) tract for *in vitro* polyadenylation (Pardi et al., 2018). The core components are bacteriophage RNA polymerase, nucleotide triphosphates (NTPs), and a capping strategy. Early methods used cap analogs like the Anti-Reverse Cap Analog (ARCA) added co-transcriptionally to ensure proper orientation and prevent reverse incorporation (Stepinski, Waddell, Stolarski, Darzynkiewicz, & Rhoads, 2001). However, the industry standard has shifted toward post-transcriptional enzymatic capping using vaccinia virus capping enzyme and 2'-O-methyltransferase to generate the Cap 1 structure (7mGpppN1m-), which is naturally recognized by eukaryotic translation initiation factor 4E (eIF4E) and is significantly less immunogenic than Cap 0 structures (Henderson et al., 2021).

2. Key Modifications for Therapeutic Efficacy

The innate immune system is exquisitely tuned to detect viral RNA through pattern recognition receptors (PRRs) like Toll-like receptors (TLR3, TLR7, TLR8) and cytosolic sensors (RIG-I, MDA5). Unmodified IVT mRNA is a potent ligand for these receptors, leading to interferon (IFN) activation and a global shutdown of translation—the very process needed for therapeutic efficacy (Alexopoulou, Holt, Medzhitov, & Flavell, 2001; Hornung et al., 2006). The field's pivotal breakthrough was the demonstration by Karikó and Weissman that incorporating naturally occurring modified nucleosides, specifically pseudouridine (Ψ) or N1-methylpseudouridine (m1Ψ), into IVT mRNA dramatically reduced activation of TLRs and protein kinase R (PKR) (Karikó et al., 2005, 2008). This suppression of the innate immune response led to a substantial increase in protein expression in mammalian cells by preventing translational inhibition and mRNA degradation (Anderson et al., 2011). Beyond immunomodulation, nucleoside modifications can also enhance translational fidelity and stability (Eyler et al., 2019).

Sequence Optimization is equally critical. Codon optimization, which replaces rare codons with synonymous, host-preferred codons, enhances translational efficiency by matching the abundant tRNA pool, thereby increasing protein yield without altering the amino acid sequence (Gustafsson et al., 2004). UTR engineering involves replacing native UTRs with well-characterized, stable UTRs from highly expressed genes (e.g., human α-globin and β-globin) to provide predictable, high-level translation (Asrani et al., 2018). Furthermore, optimizing GC content and minimizing complex secondary structures in the 5' UTR can facilitate more efficient ribosome scanning and initiation (Leppek et al., 2022).

Purification is a final, critical step to remove immunogenic byproducts of the IVT reaction, particularly double-stranded RNA (dsRNA) contaminants, which are potent activators of MDA5 and PKR (Weissman, Pardi, Muramatsu, & Karikó, 2013). High-performance liquid chromatography (HPLC) and cellulose-based purification methods have become standard for producing clinical-grade mRNA with minimal dsRNA content (Baiersdörfer et al., 2019).

3. Advanced mRNA Formats

i. Self-Amplifying mRNA (saRNA): Derived from the genome of positive-sense RNA viruses like alphaviruses, saRNA encodes both the antigen of interest and a viral replicase complex (e.g., nsP1-4). Upon delivery, the replicase amplifies the RNA strand intracellularly, leading to much

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

higher and more prolonged antigen expression from a dramatically lower initial dose compared to conventional mRNA (Geall et al., 2012). However, this comes with increased complexity, a larger payload size (~9-12 kb), and inherent immunogenicity from the replicase itself (Bloom, van den Berg, & Arbuthnot, 2021).

ii. Circular RNA (circRNA): Engineered as covalently closed, single-stranded loops without free 5' or 3' ends, circRNAs are resistant to exonuclease-mediated decay (Chen & Wang, 2022). This architecture offers the potential for extremely long-lasting protein expression (weeks to months) from a single administration. A major challenge has been enabling cap-independent translation, often solved by incorporating internal ribosome entry site (IRES) elements or engineering N6-methyladenosine (m6A) sites to recruit initiation factors (Wesselhoeft et al., 2019).



Figure 1. Innate immune sensing of mRNA vaccines

Innate immune sensing of two types of mRNA vaccine by a dendritic cell (DC), with RNA sensors shown in yellow, antigen in red, DC maturation factors in green, and peptide–major histocompatibility complex (MHC) complexes in light blue and red; an example lipid nanoparticle carrier is shown at the top right. A non-exhaustive list of the major known RNA sensors that contribute to the recognition of double-stranded and unmodified single-stranded RNAs is shown. Unmodified, unpurified (part **a**) and nucleoside-modified, fast protein liquid chromatography (FPLC)-purified (part **b**) mRNAs were selected for illustration of two formats of mRNA vaccines where known forms of mRNA sensing are present and absent, respectively. The dashed arrow represents reduced antigen expression. Ag, antigen; PKR, interferon-induced, double-stranded RNA-activated protein kinase; MDA5, interferon-induced helicase C domain-containing protein 1 (also known as IFIH1); IFN, interferon; m1Ψ, 1-methylpseudouridine; OAS, 2′–5′-oligoadenylate synthetase; TLR, Toll-like receptor. Figure (1) Engineering and delivery of synthetic mRNA. Schematic created using BioRender.com, incorporating design concepts from Pardi et al. (2018) and delivery mechanisms from Hou et al. (2021).

Delivery Technologies: The Bridge to Clinical Reality

1. The Delivery Imperative

Naked mRNA is rapidly degraded by extracellular ribonucleases (RNases), cannot cross the anionic phospholipid bilayer of cell membranes due to its large size and negative charge, and is sequestered in endosomes after endocytosis, destined for lysosomal degradation (Dowdy, 2017). An effective delivery system must therefore fulfill three key functions: (1) protect the mRNA cargo during systemic transit, (2) facilitate cellular uptake, and (3) enable endosomal escape to release the functional mRNA into the cytosol for translation (Hou et al., 2021).

2. Lipid Nanoparticles (LNPs): The Leading Platform

The clinical success of mRNA vaccines and therapies is inextricably linked to the development of safe and effective LNPs. Modern LNPs are sophisticated, multi-component systems (Cullis & Hope, 2017):

i. Ionizable Lipid: The most critical functional component. It is cationic at low pH (aiding mRNA encapsulation) and neutrally charged at physiological pH (reducing toxicity). In the acidic

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

environment of the endosome, it becomes protonated, enabling interaction with anionic endosomal lipids to induce membrane destabilization and pore formation, facilitating mRNA release (Semple et al., 2010). Key examples include DLin-MC3-DMA (used in the first approved siRNA drug, Onpattro), SM-102 (Moderna's COVID-19 vaccine), and ALC-0315 (Pfizer-BioNTech's COVID-19 vaccine) (Corbett et al., 2020; Hassett et al., 2021).

ii. Phospholipid (e.g., Distearoylphosphatidylcholine, DSPC): Provides structural integrity to the LNP bilayer, contributing to stability and fusion characteristics.

iii. Cholesterol: Stabilizes the LNP bilayer structure and enhances membrane fluidity and fusion capacity.

iv. PEGylated Lipid: A polyethylene glycol (PEG)-conjugated lipid that shields the particle surface, modulates particle size, prevents aggregation, and reduces nonspecific protein adsorption and rapid clearance by the mononuclear phagocyte system (MPS). A significant drawback is the potential induction of anti-PEG antibodies, which can cause accelerated blood clearance and reduced efficacy upon repeated dosing (Abu Lila, Kiwada, & Ishida, 2013).

LNPs are typically formulated via rapid mixing of an ethanol phase containing lipids with an aqueous phase containing mRNA in a microfluidic device, producing particles of ~80-100 nm with high encapsulation efficiency (>90%) (Belliveau et al., 2012).

3. Targeting and Route of Administration

Following intravenous administration, current LNPs predominantly accumulate in the liver due to apolipoprotein E (ApoE) adsorption and subsequent uptake by hepatocytes via low-density lipoprotein receptor (LDLR) mediated endocytosis (Akinc et al., 2019). For applications beyond hepatocytes, active targeting strategies are under intense investigation. This includes engineering LNPs with different lipid chemistries to alter organ tropism (e.g., to lung or spleen), or decorating their surface with targeting ligands such as antibodies, peptides, or small molecules to direct them to specific cell types (e.g., immune cells, endothelial cells) (Cheng et al., 2020). The route of administration itself is a powerful targeting tool; intramuscular injection localizes expression primarily to muscle and resident antigen-presenting cells, while intratumoral or intracranial injection directly targets the disease site.

4. Alternative Delivery Systems

While LNPs dominate, other platforms are being explored:

i. Polymeric Nanoparticles: Using cationic or ionizable polymers like polyethylenimine (PEI) or biodegradable poly(beta-amino esters) (PBAEs) that complex mRNA via electrostatic interactions (Kowalski, Rudra, Miao, & Anderson, 2019).

ii. Peptide-Based Systems: Cell-penetrating peptides (CPPs) or fusogenic peptides designed to condense mRNA and enhance cellular uptake and endosomal escape (Udhayakumar et al., 2021).

iii. Conjugate Technologies: Direct covalent conjugation of mRNA to targeting ligands (e.g., GalNAc for hepatocyte targeting) or polymers to improve stability and pharmacokinetics (Springer & Dowdy, 2018).



Fig 2: Ethanol Loading Formulation Process for LNP Containing Oligonucleotides Such as siRNA. Figure (3) Engineering and delivery of synthetic mRNA. Schematic created using BioRender.com, incorporating design concepts from Cullis & Hope, (2017).

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

Therapeutic Applications: An Expanding Universe

1. Prophylactic Vaccines

i. Infectious Diseases: Beyond COVID-19, active clinical programs for influenza (seeking improved breadth and durability), RSV, HIV, Zika, Nipah, and Epstein-Barr Virus. Advantages: rapid response to pandemic threats and variant updates.
ii. Generalizable Advantage: mRNA vaccines induce strong CD4+ T cell, CD8+ T cell, and neutralizing antibody responses. LNPs have intrinsic adjuvant properties, potently activating follicular helper T cells and germinal center B cell responses (Laczko et al., 2020).

2. Therapeutic Vaccines

i. Oncology (Cancer Immunotherapy): Personalized Neoantigen Vaccines: Tumor sequencing identifies patient-specific mutations. mRNA encoding these neoantigens is manufactured and administered to prime T cells to attack the tumor. Promising data in melanoma (Moderna/Merck) (Sahin et al., 2020). Also, vaccines for shared tumor-associated antigens (e.g., TAA, CEA).
ii. Other: Therapeutic vaccines for chronic infections (e.g., herpes simplex virus, hepatitis B).

3. Protein Replacement and Regenerative Therapy

i. *In vivo* Protein Production: mRNA acts as a temporary blueprint to produce proteins inside the patient's own cells, overcoming challenges of recombinant protein manufacturing, stability, and delivery.
ii. Rare Diseases: Clinical trials for methylmalonic acidemia (propionic enzyme), cystic fibrosis (CFTR protein), glycogen storage disease (Rohner et al., 2022).
iii. Regenerative Medicine: mRNA encoding VEGF for angiogenesis in heart disease; BMP-2 for bone growth; factors for tissue repair (Zangi et al., 2013).
iv. Advantage: Transient expression is ideal for many signaling proteins, reducing risks of genomic integration or long-term overexpression.

4. Gene Editing and Cellular Reprogramming

i. Non-viral CRISPR-Cas9 Delivery: mRNA encoding the Cas9 nuclease (and a separate guide RNA) allows transient, high-efficiency expression of the editing machinery, significantly reducing off-target risks compared to stable viral expression. Used ex vivo (engineer CAR-T cells) and *in vivo* (e.g., for transthyretin amyloidosis) (Finn et al., 2018).
ii. Cell Fate Reprogramming: mRNA cocktails of transcription factors can directly reprogram somatic cells (e.g., fibroblasts into cardiomyocytes or neurons) for regenerative purposes (Warren et al., 2010).

Challenges and Future Perspectives

1. Persistent Challenges

i. Precision Delivery: Achieving efficient, specific delivery to non-liver tissues (e.g., lungs, heart, brain, specific immune cells) remains a primary hurdle (Dammes & Peer, 2020).
ii. Durability & Redosing: For many chronic conditions, protein expression from current mRNA lasts days to a week. Solutions include saRNA, circRNA, or improved formulations. Anti-PEG immunity and anti-drug antibodies can limit repeat dosing.
iii. Scalability & Cost: While scalable, GMP manufacturing of mRNA-LNPs is complex. Reducing cost is critical for global health equity (Kis, Shah, & Sato, 2022).
iv. Long-Term Safety: Continued pharmacovigilance is essential. Areas of monitoring include: rare adverse events (e.g., myocarditis), lipid carrier toxicology, and long-term immunological effects of repeated LNP administration.

2. Future Directions

i. Next-Generation Constructs: Clinical translation of circRNA and optimized saRNA for durable expression.

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

ii. Programmable Therapeutics: "Smart" mRNA systems responsive to cellular cues or small molecules for controlled protein expression.



Figure 3 Schematic Representation of Extra- and Intracellular Barriers for mRNA Delivery Figure (3) Engineering and delivery of synthetic mRNA. Schematic created using BioRender.com, incorporating design concepts from Kowalski et al., (2019).

iii. Disease Prevention: Potential for multi-valent pandemic-preparedness vaccines or routine cancer prevention vaccines (e.g., for KRAS-mutant pre-cancers).
iv. Integration with Other Modalities: Combining mRNA vaccines with checkpoint inhibitors in oncology, or mRNA-encoded antibodies with small molecules.
v. Expansion into New Diseases: Neurological disorders, autoimmune diseases, metabolic conditions, and more.

Conclusion

The mRNA technology platform has irrevocably changed the landscape of medicine. Its journey from a fundamental biological concept to a validated clinical powerhouse is a testament to decades of basic science and persistent innovation. By harnessing and refining the cell's own translational machinery, mRNA therapeutics offer a unique combination of speed, flexibility, efficacy, and manufacturability. While challenges in delivery, durability, and cost remain active frontiers of research, the trajectory is clear. mRNA is not a one-pandemic

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

wonder but a foundational pillar of 21st-century biomedicine, poised to deliver a new generation of treatments for some of humanity's most intractable diseases. The future will be written, in part, in the language of messenger RNA.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgment

We would like to thank the National Reseach Centre, Egypt.

References

Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013). The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage. Journal of Controlled Release, 172(1), 38–47. https://doi.org/10.1016/j.jconrel.2013.07.026

Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., Mui, B. L., Semple, S. C., Tam, Y. K., Ciufolini, M., Witzigmann, D., Kulkarni, J. A., van der Meel, R., & Cullis, P. R. (2019). The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nature Nanotechnology, 14(12), 1084–1087. https://doi.org/10.1038/s41565-019-0591-y

Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001). Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature, 413(6857), 732–738. https://doi.org/10.1038/35099560

Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2011). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Research, 38(17), 5884–5892. https://doi.org/10.1093/nar/gkr347

Asrani, K. H., Farelli, J. D., Stahley, M. R., Miller, R. L., Cheng, C. J., Subramanian, R. R., & Brown, J. M. (2018). Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biology, 15(6), 756–762. https://doi.org/10.1080/15476286.2018.1450054

Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019). A facile method for the removal of dsRNA contaminant from *in vitro*-transcribed mRNA. Molecular Therapy - Nucleic Acids, 15, 26–35. https://doi.org/10.1016/j.omtn.2019.02.018

Beckert, B., & Masquida, B. (2011). Synthesis of RNA by *in vitro* transcription. In RNA (pp. 29–41). Humana Press. https://doi.org/10.1007/978-1-59745-248-9_3

Belliveau, N. M., Huft, J., Lin, P. J., Chen, S., Leung, A. K., Leaver, T. J., Wild, A. W., Lee, J. B., Taylor, R. J., Tam, Y. K., Hansen, C. L., & Cullis, P. R. (2012). Microfluidic synthesis of highly potent limit-size lipid nanoparticles for *in vivo* delivery of siRNA. Molecular Therapy - Nucleic Acids, 1, e37. https://doi.org/10.1038/mtna.2012.28

Bloom, K., van den Berg, F., & Arbuthnot, P. (2021). Self-amplifying RNA vaccines for infectious diseases. Gene Therapy, 28(3–4), 117–129. https://doi.org/10.1038/s41434-020-00204-y

Brenner, S., Jacob, F., & Meselson, M. (1961). An unstable intermediate carrying information from genes to ribosomes for protein synthesis. Nature, 190, 576–581. https://doi.org/10.1038/190576a0

Chen, R., & Wang, S. K. (2022). Circular RNAs in physiology and non-immunological diseases. Trends in Biochemical Sciences, 47(3), 250–264. https://doi.org/10.1016/j.tibs.2021.08.006

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

Cheng, Q., Wei, T., Jia, Y., Farbiak, L., Zhou, K., Zhang, S., Wei, Y., Zhu, H., & Siegwart, D. J. (2020). Dendrimer-based lipid nanoparticles deliver therapeutic FAH mRNA to normalize liver function and extend survival in a mouse model of hepatorenal tyrosinemia type I. Advanced Materials, 32(52), 2003537. https://doi.org/10.1002/adma.202003537

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 586(7830), 567–571. https://doi.org/10.1038/s41586-020-2622-0

Cullis, P. R., & Hope, M. J. (2017). Lipid nanoparticle systems for enabling gene therapies. Molecular Therapy, 25(7), 1467–1475. https://doi.org/10.1016/j.ymthe.2017.03.013

Dammes, N., & Peer, D. (2020). Paving the road for RNA therapeutics. Trends in Pharmacological Sciences, 41(10), 755–775. https://doi.org/10.1016/j.tips.2020.08.004

Dowdy, S. F. (2017). Overcoming cellular barriers for RNA therapeutics. Nature Biotechnology, 35(3), 222–229. https://doi.org/10.1038/nbt.3802

Eyler, D. E., Franco, M. K., Batool, Z., Wu, M. Z., Dubuke, M. L., Dobosz-Bartoszek, M., Jones, J. D., Polikanov, Y. S., Roy, B., & Koutmou, K. S. (2019). Pseudouridinylation of mRNA coding sequences alters translation. Proceedings of the National Academy of Sciences, 116(46), 23068–23074. https://doi.org/10.1073/pnas.1821754116

Finn, J. D., Smith, A. R., Patel, M. C., Shaw, L., Youniss, M. R., van Heteren, J., Dirstine, T., Ciullo, C., Lescarbeau, R., Seitzer, J., Shah, R. R., Shah, A., Ling, D., Growe, J., Pink, M., Rohde, E., Wood, K. M., Salomon, W. E., Harrington, W. F., … Morrissey, D. V. (2018). A single administration of CRISPR/Cas9 lipid nanoparticles achieves robust and persistent *in vivo* genome editing. Cell Reports, 22(9), 2227–2235. https://doi.org/10.1016/j.celrep.2018.02.014

Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., O'Hagan, D. T., Singh, M., Mason, P. W., Valiante, N. M., Dormitzer, P. R., Barnett, S. W., Rappuoli, R., Ulmer, J. B., & Mandl, C. W. (2012). Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences, 109(36), 14604–14609. https://doi.org/10.1073/pnas.1209367109

Gustafsson, C., Govindarajan, S., & Minshull, J. (2004). Codon bias and heterologous protein expression. Trends in Biotechnology, 22(7), 346–353. https://doi.org/10.1016/j.tibtech.2004.04.006

Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A. (2021). Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Molecular Therapy - Nucleic Acids, 25, 1–11. https://doi.org/10.1016/j.omtn.2021.07.003

Henderson, J. M., Ujita, A., Hill, E., Yousif-Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla-Powers, J. R., & Houston, M. E. (2021). Cap 1 messenger RNA synthesis with co-transcriptional CleanCap® analog by *in vitro* transcription. Current Protocols, 1(2), e39. https://doi.org/10.1002/cpz1.39

Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K. K., Schlee, M., Endres, S., & Hartmann, G. (2006). 5'-Triphosphate RNA is the ligand for RIG-I. Science, 314(5801), 994–997. https://doi.org/10.1126/science.1132505

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net

RICOS BIOLOGY Journal
2026, Vol. 4, No. 01, 1-11
doi: https://doi.org/10.33687/ricosbiol.04.01.106

Hou, X., Zaks, T., Langer, R., & Dong, Y. (2021). Lipid nanoparticles for mRNA delivery. Nature Reviews Materials, 6(12), 1078–1094. https://doi.org/10.1038/s41578-021-00358-0

Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2), 165–175. https://doi.org/10.1016/j.immuni.2005.06.008

Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Molecular Therapy, 16(11), 1833–1840. https://doi.org/10.1038/mt.2008.200

Kis, Z., Shah, N., & Sato, Y. (2022). The future of vaccine manufacturing: Leveraging disruptive technologies to improve global health. Journal of Pharmaceutical Sciences, 111(5), 1241–1249. https://doi.org/10.1016/j.xphs.2021.12.013

Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019). Delivering the messenger: Advances in technologies for therapeutic mRNA delivery. Molecular Therapy, 27(4), 710–728. https://doi.org/10.1016/j.ymthe.2019.02.012

Laczko, D., Hogan, M. J., Toulmin, S. A., Hicks, P., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., Ojha, A., Zhang, L., Mu, Z., Parks, R., Manzoni, T. B., Roper, B., Strohmeier, S., Tombácz, I., Arwood, L., … Weissman, D. (2020). A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity, 53(4), 724-732.e7. https://doi.org/10.1016/j.immuni.2020.07.019

Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., Tiu, G. C., Wellington-Oguri, R., Fujii, K., Sharma, E., Watkins, A. M., Nicol, J. J., Romano, J., Tunguz, B., Diaz, F., … Das, R. (2022). Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nature Communications, 13(1), 1536. https://doi.org/10.1038/s41467-022-28776-w

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines — a new era in vaccinology. Nature Reviews Drug Discovery, 17(4), 261–279. https://doi.org/10.1038/nrd.2017.243

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., … Gruber, W. C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 383(27), 2603–2615. https://doi.org/10.1056/NEJMoa2034577

Rohner, E., Yang, R., Foo, K. S., Goedel, A., & Chien, K. R. (2022). Unlocking the promise of mRNA therapeutics. Nature Biotechnology, 40(11), 1586–1600. https://doi.org/10.1038/s41587-022-01491-z

Sahin, U., Oehm, P., Derhovanessian, E., Jabulowsky, R. A., Vormehr, M., Gold, M., Maurus, D., Schwarck-Kokarakis, D., Kuhn, A. N., Omokoko, T., Kranz, L. M., Diken, M., Kreiter, S., Haas, H., Attig, S., Rae, R., Cuk, K., Kemmer-Brück, A., Breitkreuz, A., … Türeci, Ö. (2020). An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 585(7823), 107–112. https://doi.org/10.1038/s41586-020-2537-8

Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W., Stebbing, D., Crosley, E. J., Yaworski, E., Hafez, I. M., Dorkin, J. R., Qin, J., Lam, K., Rajeev, K. G., Wong, K. F., Jeffs, L. B., Nechev, L., Eisenhardt, M. L., … Hope, M. J. (2010). Rational design of cationic lipids for siRNA delivery. Nature Biotechnology, 28(2), 172–176. https://doi.org/10.1038/nbt.1602

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg

Springer, A. D., & Dowdy, S. F. (2018). GalNAc-siRNA conjugates: Leading the way for delivery of RNAi therapeutics. Nucleic Acid Therapeutics, 28(3), 109–118. https://doi.org/10.1089/nat.2018.0736

Stepinski, J., Waddell, C., Stolarski, R., Darzynkiewicz, E., & Rhoads, R. E. (2001). Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG. RNA, 7(10), 1486–1495. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1370193/

Udhayakumar, V. K., De Beuckelaer, A., McCaffrey, J., McCrudden, C. M., Kirschman, J. L., Vanover, D., Van Hoecke, L., Roose, K., Deswarte, K., De Geest, B. G., Lienenklaus, S., & De Koker, S. (2021). Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide. Advanced Healthcare Materials, 10(7), 2001652. https://doi.org/10.1002/adhm.202001652

Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., Daley, G. Q., Brack, A. S., Collins, J. J., Cowan, C., Schlaeger, T. M., & Rossi, D. J. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell, 7(5), 618–630. https://doi.org/10.1016/j.stem.2010.08.012

Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013). HPLC purification of *in vitro* transcribed long RNA. Methods in Molecular Biology, 969, 43–54. https://doi.org/10.1007/978-1-62703-260-5_3

Wesselhoeft, R. A., Kowalski, P. S., Parker-Hale, F. C., Huang, Y., Biswas, S., & Anderson, D. G. (2019). RNA circularization diminishes immunogenicity and can extend translation duration *in vivo*. Molecular Cell, 74(3), 508-520.e4. https://doi.org/10.1016/j.molcel.2019.02.015

Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990). Direct gene transfer into mouse muscle *in vivo*. Science, 247(4949 Pt 1), 1465–1468. https://doi.org/10.1126/science.1690918

Zangi, L., Lui, K. O., von Gise, A., Ma, Q., Ebina, W., Ptaszek, L. M., Später, D., Xu, H., Tabebordbar, M., Gorbatov, R., Sena, B., Nahrendorf, M., Briscoe, D. M., Li, R. A., Wagers, A. J., Rossi, D. J., Pu, W. T., & Chien, K. R. (2013). Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nature Biotechnology, 31(10), 898–907. https://doi.org/10.1038/nbt.2682

*Corresponding author: ***Abouelhag A. Hussien***
ha.abouelhag@nrc.sci.eg
Ricos Biology Journal ISSN 2959-3751 (*E*), 2959-3743 (*P*)
www.https://ricosbiology.net contact info@ricosbiology.net